IDEAYA Biosciences, Inc. (IDYA) stock
IDYANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 9/303% above fair value
$30.36−1.47 (-4.62%)
Close on Nov 16, 2026Market cap $2.93BP/E –Yield –
IDEAYA Biosciences r&d expenses
Research and development expenses are spending on new products and technology.
IDEAYA Biosciences's R&D Expenses for the twelve months ending Jun 30, 2026 was $374.01M, up 9.2% year over year. For fiscal 2025 it was $314.70M, up 6.8% from the year before. The highest annual figure on record is $314.70M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $314.70M | +6.8% |
| FY2024 | Dec 31, 2024 | $294.67M | +127.5% |
| FY2023 | Dec 31, 2023 | $129.51M | +44.6% |
| FY2022 | Dec 31, 2022 | $89.54M | +54.0% |
| FY2021 | Dec 31, 2021 | $58.16M | +46.5% |
| FY2020 | Dec 31, 2020 | $39.70M | +15.7% |
| FY2019 | Dec 31, 2019 | $34.32M | +8.1% |
| FY2018 | Dec 31, 2018 | $31.75M | +156.4% |
| FY2017 | Dec 31, 2017 | $12.38M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $108.69M | +46.4% |
| Q1 FY2026 | Mar 31, 2026 | $95.73M | +35.0% |
| Q4 FY2025 | Dec 31, 2025 | $86.60M | -38.2% |
| Q3 FY2025 | Sep 30, 2025 | $82.99M | +45.2% |
| Q2 FY2025 | Jun 30, 2025 | $74.23M | +36.1% |
| Q1 FY2025 | Mar 31, 2025 | $70.89M | +65.6% |
| Q4 FY2024 | Dec 31, 2024 | $140.18M | +261.6% |
| Q3 FY2024 | Sep 30, 2024 | $57.15M | +69.6% |
| Q2 FY2024 | Jun 30, 2024 | $54.53M | +86.9% |
| Q1 FY2024 | Mar 31, 2024 | $42.81M | +53.6% |
| Q4 FY2023 | Dec 31, 2023 | $38.77M | +56.9% |
| Q3 FY2023 | Sep 30, 2023 | $33.70M | +50.6% |
| Q2 FY2023 | Jun 30, 2023 | $29.18M | +28.0% |
| Q1 FY2023 | Mar 31, 2023 | $27.86M | +41.7% |
| Q4 FY2022 | Dec 31, 2022 | $24.71M | +53.4% |
| Q3 FY2022 | Sep 30, 2022 | $22.37M | +44.3% |
| Q2 FY2022 | Jun 30, 2022 | $22.80M | +52.2% |
| Q1 FY2022 | Mar 31, 2022 | $19.66M | +69.9% |
| Q4 FY2021 | Dec 31, 2021 | $16.11M | +33.7% |
| Q3 FY2021 | Sep 30, 2021 | $15.50M | +54.6% |
| Q2 FY2021 | Jun 30, 2021 | $14.98M | +74.3% |
| Q1 FY2021 | Mar 31, 2021 | $11.57M | +28.1% |
| Q4 FY2020 | Dec 31, 2020 | $12.05M | +41.1% |
| Q3 FY2020 | Sep 30, 2020 | $10.03M | +12.4% |
| Q2 FY2020 | Jun 30, 2020 | $8.60M | -3.0% |
| Q1 FY2020 | Mar 31, 2020 | $9.03M | +12.9% |
| Q4 FY2019 | Dec 31, 2019 | $8.54M | +12.7% |
| Q3 FY2019 | Sep 30, 2019 | $8.92M | -28.8% |
| Q2 FY2019 | Jun 30, 2019 | $8.86M | +37.7% |
| Q1 FY2019 | Mar 31, 2019 | $8.00M | – |
| Q4 FY2018 | Dec 31, 2018 | $7.58M | – |
| Q3 FY2018 | Sep 30, 2018 | $12.54M | – |
| Q2 FY2018 | Jun 30, 2018 | $6.43M | – |
See a number that looks wrong?